Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

Onsite Parexel experts include recently appointed Chief Medical Officer and veteran oncologist Dr. Charlotte Moser, licensed medical oncologist and Global Therapeutic Area Head, Oncology, Dr. Gwyn ...

This update will be presented as part of the OPERA-01 trial-in-progress poster at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago, Illinois.

Presenter: Eunice S. Wang, M.D. A post-hoc analysis of the pivotal cohort from the Phase 1/2 study evaluated outcomes in patients with R/R mIDH1 AML who received olutasidenib after either 1-2 or ...

FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global ...

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.